New combination treatment for advanced pancreatic cancer
TGX-1214 - Combination Strategy for the Treatment of Advanced Pancreatic Cancer
This study is testing a new treatment for advanced pancreatic cancer that combines a promising chemotherapy drug with immune boosters to help your body fight the cancer better, and you might have a chance to join the trial if you're interested!
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California at Davis NIH-funded |
| Lab location | 1 site (Davis, United States) |
| Project ID | NIH-11009524 on NIH RePORTER |
What this research studies
This research aims to develop a novel treatment strategy for advanced pancreatic cancer by combining a new chemotherapy drug, TGX-1214, with immune checkpoint inhibitors. The approach utilizes a nanoemulsion formulation of DHA-SBT-1214, which has shown promising results in preclinical models by significantly reducing tumor growth. The study will involve a multidisciplinary team from the University of California at Davis and other institutions, focusing on enhancing the immune response against pancreatic tumors. Patients may have the opportunity to participate in trials that explore this innovative treatment combination.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with advanced pancreatic ductal adenocarcinoma who have not responded to standard treatments.
Not a fit: Patients with early-stage pancreatic cancer or those who have not been diagnosed with pancreatic cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with advanced pancreatic cancer.
How similar studies have performed: Other research has shown success with similar combination therapies in treating various cancers, indicating potential for this approach in pancreatic cancer as well.
Where this research is happening
Davis, United States
- University of California at Davis — Davis, United States (Active)
Researchers
- Principal investigator: Mackenzie, Gerardo Guillermo — University of California at Davis
- Study coordinator: Mackenzie, Gerardo Guillermo
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.